A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.

Heiner WedemeyerSoo AlemanMaurizia Rossana BrunettoAntje BlankPietro AndreonePavel BogomolovVladimir ChulanovNina MamonovaNatalia GeyvandovaViacheslav MorozovOlga SagalovaTatyana StepanovaAnnemarie BergerDmitry ManuilovVithika SuriQi AnBen DaJohn FlahertyAnu OsinusiYang LiuUta MerleJulian Schulze Zur WieschStefan ZeuzemSandra CiesekMarkus CornbergPietro Lamperticonull null

Published in: The New England journal of medicine (2023)

After 48 weeks of bulevirtide treatment, HDV RNA and ALT levels were reduced in patients with chronic hepatitis D. (Funded by Gilead Sciences; MYR 301 ClinicalTrials.gov number, NCT03852719.).

Keyphrases

combination therapy
gestational age
replacement therapy